nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—DDC—telencephalic ventricle—malignant glioma	0.0635	0.197	CbGeAlD
Methyldopa—DDC—pineal body—malignant glioma	0.0551	0.171	CbGeAlD
Methyldopa—COMT—telencephalic ventricle—malignant glioma	0.042	0.13	CbGeAlD
Methyldopa—DDC—embryo—malignant glioma	0.0188	0.0582	CbGeAlD
Methyldopa—DDC—brainstem—malignant glioma	0.0172	0.0533	CbGeAlD
Methyldopa—DDC—telencephalon—malignant glioma	0.0153	0.0473	CbGeAlD
Methyldopa—VIIth nerve paralysis—Carmustine—malignant glioma	0.0119	0.0819	CcSEcCtD
Methyldopa—COMT—brainstem—malignant glioma	0.0114	0.0352	CbGeAlD
Methyldopa—DDC—midbrain—malignant glioma	0.011	0.034	CbGeAlD
Methyldopa—COMT—telencephalon—malignant glioma	0.0101	0.0313	CbGeAlD
Methyldopa—DDC—central nervous system—malignant glioma	0.00867	0.0269	CbGeAlD
Methyldopa—COMT—medulla oblongata—malignant glioma	0.00793	0.0246	CbGeAlD
Methyldopa—COMT—midbrain—malignant glioma	0.00725	0.0225	CbGeAlD
Methyldopa—COMT—spinal cord—malignant glioma	0.00707	0.0219	CbGeAlD
Methyldopa—DDC—brain—malignant glioma	0.00689	0.0213	CbGeAlD
Methyldopa—COMT—central nervous system—malignant glioma	0.00574	0.0178	CbGeAlD
Methyldopa—Endocrine disorder—Temozolomide—malignant glioma	0.00571	0.0392	CcSEcCtD
Methyldopa—Liver injury—Temozolomide—malignant glioma	0.00563	0.0386	CcSEcCtD
Methyldopa—COMT—cerebellum—malignant glioma	0.00561	0.0174	CbGeAlD
Methyldopa—Amenorrhoea—Temozolomide—malignant glioma	0.00539	0.037	CcSEcCtD
Methyldopa—ADRA2A—telencephalon—malignant glioma	0.00514	0.0159	CbGeAlD
Methyldopa—COMT—brain—malignant glioma	0.00455	0.0141	CbGeAlD
Methyldopa—Gynaecomastia—Carmustine—malignant glioma	0.00438	0.0301	CcSEcCtD
Methyldopa—Mesalazine—PPARG—malignant glioma	0.00429	0.212	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS1—malignant glioma	0.00404	0.2	CrCbGaD
Methyldopa—ADRA2A—medulla oblongata—malignant glioma	0.00404	0.0125	CbGeAlD
Methyldopa—Nasal congestion—Temozolomide—malignant glioma	0.00377	0.0259	CcSEcCtD
Methyldopa—ADRA2A—midbrain—malignant glioma	0.00369	0.0114	CbGeAlD
Methyldopa—ADRA2A—spinal cord—malignant glioma	0.0036	0.0112	CbGeAlD
Methyldopa—Liver function test abnormal—Carmustine—malignant glioma	0.00328	0.0225	CcSEcCtD
Methyldopa—Mesalazine—PTGS1—malignant glioma	0.00317	0.157	CrCbGaD
Methyldopa—Breast disorder—Temozolomide—malignant glioma	0.00311	0.0213	CcSEcCtD
Methyldopa—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.0031	0.0212	CcSEcCtD
Methyldopa—Abdominal distension—Temozolomide—malignant glioma	0.00299	0.0205	CcSEcCtD
Methyldopa—ADRA2A—central nervous system—malignant glioma	0.00292	0.00905	CbGeAlD
Methyldopa—Pancytopenia—Carmustine—malignant glioma	0.00292	0.02	CcSEcCtD
Methyldopa—ADRA2A—cerebellum—malignant glioma	0.00285	0.00885	CbGeAlD
Methyldopa—Pancytopenia—Temozolomide—malignant glioma	0.00282	0.0194	CcSEcCtD
Methyldopa—Erectile dysfunction—Temozolomide—malignant glioma	0.00274	0.0188	CcSEcCtD
Methyldopa—Weight increased—Temozolomide—malignant glioma	0.0027	0.0186	CcSEcCtD
Methyldopa—Infestation NOS—Temozolomide—malignant glioma	0.00265	0.0182	CcSEcCtD
Methyldopa—Infestation—Temozolomide—malignant glioma	0.00265	0.0182	CcSEcCtD
Methyldopa—Hepatobiliary disease—Temozolomide—malignant glioma	0.00251	0.0172	CcSEcCtD
Methyldopa—Dopamine—SLC6A3—malignant glioma	0.00242	0.12	CrCbGaD
Methyldopa—Connective tissue disorder—Carmustine—malignant glioma	0.00242	0.0166	CcSEcCtD
Methyldopa—Hepatitis—Temozolomide—malignant glioma	0.00238	0.0163	CcSEcCtD
Methyldopa—Connective tissue disorder—Temozolomide—malignant glioma	0.00234	0.016	CcSEcCtD
Methyldopa—ADRA2A—brain—malignant glioma	0.00232	0.00719	CbGeAlD
Methyldopa—Aminosalicylic Acid—PTGS2—malignant glioma	0.00231	0.114	CrCbGaD
Methyldopa—Cardiac disorder—Temozolomide—malignant glioma	0.00221	0.0151	CcSEcCtD
Methyldopa—Epinephrine—TNF—malignant glioma	0.0022	0.109	CrCbGaD
Methyldopa—Angiopathy—Temozolomide—malignant glioma	0.00216	0.0148	CcSEcCtD
Methyldopa—Mental disorder—Carmustine—malignant glioma	0.00216	0.0148	CcSEcCtD
Methyldopa—Mediastinal disorder—Temozolomide—malignant glioma	0.00214	0.0147	CcSEcCtD
Methyldopa—Mental disorder—Temozolomide—malignant glioma	0.00208	0.0143	CcSEcCtD
Methyldopa—Leukopenia—Carmustine—malignant glioma	0.00192	0.0132	CcSEcCtD
Methyldopa—Leukopenia—Temozolomide—malignant glioma	0.00185	0.0127	CcSEcCtD
Methyldopa—Myalgia—Carmustine—malignant glioma	0.00182	0.0125	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—malignant glioma	0.00181	0.0895	CrCbGaD
Methyldopa—Myalgia—Temozolomide—malignant glioma	0.00176	0.0121	CcSEcCtD
Methyldopa—Arthralgia—Temozolomide—malignant glioma	0.00176	0.0121	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00175	0.012	CcSEcCtD
Methyldopa—Oedema—Carmustine—malignant glioma	0.00175	0.012	CcSEcCtD
Methyldopa—Infection—Carmustine—malignant glioma	0.00174	0.0119	CcSEcCtD
Methyldopa—Thrombocytopenia—Carmustine—malignant glioma	0.00171	0.0117	CcSEcCtD
Methyldopa—Oedema—Temozolomide—malignant glioma	0.00169	0.0116	CcSEcCtD
Methyldopa—Infection—Temozolomide—malignant glioma	0.00168	0.0115	CcSEcCtD
Methyldopa—Nervous system disorder—Temozolomide—malignant glioma	0.00166	0.0114	CcSEcCtD
Methyldopa—Thrombocytopenia—Temozolomide—malignant glioma	0.00165	0.0113	CcSEcCtD
Methyldopa—Skin disorder—Temozolomide—malignant glioma	0.00164	0.0113	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00159	0.0109	CcSEcCtD
Methyldopa—Paraesthesia—Carmustine—malignant glioma	0.00157	0.0108	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00154	0.0106	CcSEcCtD
Methyldopa—Paraesthesia—Temozolomide—malignant glioma	0.00152	0.0104	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Carmustine—malignant glioma	0.00151	0.0104	CcSEcCtD
Methyldopa—Constipation—Carmustine—malignant glioma	0.00149	0.0103	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Temozolomide—malignant glioma	0.00146	0.01	CcSEcCtD
Methyldopa—Constipation—Temozolomide—malignant glioma	0.00144	0.00991	CcSEcCtD
Methyldopa—Body temperature increased—Carmustine—malignant glioma	0.00138	0.00948	CcSEcCtD
Methyldopa—Body temperature increased—Temozolomide—malignant glioma	0.00134	0.00916	CcSEcCtD
Methyldopa—Hypersensitivity—Carmustine—malignant glioma	0.00129	0.00884	CcSEcCtD
Methyldopa—Asthenia—Carmustine—malignant glioma	0.00125	0.00861	CcSEcCtD
Methyldopa—Hypersensitivity—Temozolomide—malignant glioma	0.00124	0.00854	CcSEcCtD
Methyldopa—Asthenia—Temozolomide—malignant glioma	0.00121	0.00832	CcSEcCtD
Methyldopa—Diarrhoea—Carmustine—malignant glioma	0.0012	0.00821	CcSEcCtD
Methyldopa—Dizziness—Carmustine—malignant glioma	0.00116	0.00793	CcSEcCtD
Methyldopa—Diarrhoea—Temozolomide—malignant glioma	0.00116	0.00793	CcSEcCtD
Methyldopa—Dizziness—Temozolomide—malignant glioma	0.00112	0.00767	CcSEcCtD
Methyldopa—Vomiting—Carmustine—malignant glioma	0.00111	0.00763	CcSEcCtD
Methyldopa—Rash—Carmustine—malignant glioma	0.0011	0.00756	CcSEcCtD
Methyldopa—Dermatitis—Carmustine—malignant glioma	0.0011	0.00756	CcSEcCtD
Methyldopa—Headache—Carmustine—malignant glioma	0.0011	0.00751	CcSEcCtD
Methyldopa—Vomiting—Temozolomide—malignant glioma	0.00107	0.00737	CcSEcCtD
Methyldopa—Rash—Temozolomide—malignant glioma	0.00107	0.00731	CcSEcCtD
Methyldopa—Dermatitis—Temozolomide—malignant glioma	0.00106	0.0073	CcSEcCtD
Methyldopa—Headache—Temozolomide—malignant glioma	0.00106	0.00726	CcSEcCtD
Methyldopa—Nausea—Carmustine—malignant glioma	0.00104	0.00712	CcSEcCtD
Methyldopa—Nausea—Temozolomide—malignant glioma	0.001	0.00689	CcSEcCtD
Methyldopa—DDC—SIDS Susceptibility Pathways—IL1B—malignant glioma	0.000842	0.00165	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—CASP3—malignant glioma	0.00084	0.00164	CbGpPWpGaD
Methyldopa—COMT—Metabolism—COX8A—malignant glioma	0.000833	0.00163	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—BRAF—malignant glioma	0.000815	0.00159	CbGpPWpGaD
Methyldopa—DDC—Metabolism—ASMT—malignant glioma	0.000797	0.00156	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CCR4—malignant glioma	0.000792	0.00155	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BCAN—malignant glioma	0.00075	0.00147	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CCR4—malignant glioma	0.000735	0.00144	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—VEGFA—malignant glioma	0.000713	0.00139	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ASMT—malignant glioma	0.000708	0.00138	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—MDM2—malignant glioma	0.000683	0.00134	CbGpPWpGaD
Methyldopa—COMT—Transmission across Chemical Synapses—RAF1—malignant glioma	0.000681	0.00133	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BCAN—malignant glioma	0.000666	0.0013	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ATP1B2—malignant glioma	0.000652	0.00128	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—PTEN—malignant glioma	0.000644	0.00126	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CCR4—malignant glioma	0.00063	0.00123	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—BRAF—malignant glioma	0.000625	0.00122	CbGpPWpGaD
Methyldopa—DDC—SIDS Susceptibility Pathways—TNF—malignant glioma	0.000611	0.00119	CbGpPWpGaD
Methyldopa—DDC—Metabolism—IDH2—malignant glioma	0.000604	0.00118	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCR3—malignant glioma	0.000589	0.00115	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—RTEL1—malignant glioma	0.000576	0.00113	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—TFRC—malignant glioma	0.000575	0.00112	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP2B6—malignant glioma	0.000568	0.00111	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—CXCR3—malignant glioma	0.000546	0.00107	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—BDKRB2—malignant glioma	0.000538	0.00105	CbGpPWpGaD
Methyldopa—COMT—Metabolism—IDH2—malignant glioma	0.000537	0.00105	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	0.000528	0.00103	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—MDM2—malignant glioma	0.000523	0.00102	CbGpPWpGaD
Methyldopa—COMT—Neuronal System—RAF1—malignant glioma	0.000521	0.00102	CbGpPWpGaD
Methyldopa—DDC—Metabolism—IDH1—malignant glioma	0.00052	0.00102	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—KNG1—malignant glioma	0.000514	0.00101	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet Aggregation (Plug Formation)—AKT1—malignant glioma	0.000507	0.000992	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP2B6—malignant glioma	0.000504	0.000986	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	0.000503	0.000983	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SPHK1—malignant glioma	0.000503	0.000983	CbGpPWpGaD
Methyldopa—ADRA2A—GPCRs, Class A Rhodopsin-like—BDKRB2—malignant glioma	0.0005	0.000977	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CYP2C18—malignant glioma	0.000493	0.000963	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—KNG1—malignant glioma	0.00049	0.000958	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ANGPT2—malignant glioma	0.000481	0.000941	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CCR4—malignant glioma	0.000479	0.000938	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—SOD1—malignant glioma	0.000478	0.000934	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCR3—malignant glioma	0.000468	0.000915	CbGpPWpGaD
Methyldopa—COMT—Metabolism—IDH1—malignant glioma	0.000461	0.000902	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SPHK1—malignant glioma	0.000446	0.000873	CbGpPWpGaD
Methyldopa—DDC—Circadian rythm related genes—TP53—malignant glioma	0.00044	0.000859	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PTK2—malignant glioma	0.000439	0.000858	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CYP2C18—malignant glioma	0.000437	0.000855	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—BDKRB2—malignant glioma	0.000428	0.000837	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—HIST1H3B—malignant glioma	0.000417	0.000814	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—MYB—malignant glioma	0.000413	0.000807	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LATS2—malignant glioma	0.00041	0.000801	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTT1—malignant glioma	0.000398	0.000779	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—KNG1—malignant glioma	0.000389	0.000761	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS1—malignant glioma	0.000373	0.00073	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PDGFB—malignant glioma	0.000369	0.000721	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCR3—malignant glioma	0.000356	0.000697	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTT1—malignant glioma	0.000354	0.000692	CbGpPWpGaD
Methyldopa—DDC—Metabolism—BCHE—malignant glioma	0.000347	0.000679	CbGpPWpGaD
Methyldopa—DDC—Metabolism—SLC5A5—malignant glioma	0.000343	0.00067	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—F2—malignant glioma	0.000332	0.00065	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—FN1—malignant glioma	0.000332	0.00065	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS1—malignant glioma	0.000331	0.000648	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COX8A—malignant glioma	0.000331	0.000647	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—BDKRB2—malignant glioma	0.000326	0.000637	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—H3F3A—malignant glioma	0.000322	0.000629	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CG—malignant glioma	0.000318	0.000622	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—EGF—malignant glioma	0.000314	0.000615	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LATS1—malignant glioma	0.00031	0.000607	CbGpPWpGaD
Methyldopa—COMT—Metabolism—BCHE—malignant glioma	0.000308	0.000603	CbGpPWpGaD
Methyldopa—COMT—Metabolism—SLC5A5—malignant glioma	0.000304	0.000595	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—KNG1—malignant glioma	0.000297	0.00058	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT2—malignant glioma	0.000291	0.000569	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ASMT—malignant glioma	0.000281	0.00055	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CD—malignant glioma	0.00028	0.000547	CbGpPWpGaD
Methyldopa—DDC—Metabolism—GSTP1—malignant glioma	0.000276	0.00054	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR4—malignant glioma	0.000271	0.00053	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAT—malignant glioma	0.000269	0.000525	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KNG1—malignant glioma	0.000265	0.000518	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCAN—malignant glioma	0.000265	0.000517	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IFNA2—malignant glioma	0.00026	0.000508	CbGpPWpGaD
Methyldopa—DDC—Metabolism—NCOR1—malignant glioma	0.000254	0.000496	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—F2—malignant glioma	0.000252	0.000492	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—RAF1—malignant glioma	0.00025	0.000488	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SOD1—malignant glioma	0.000246	0.000481	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR4—malignant glioma	0.000246	0.000481	CbGpPWpGaD
Methyldopa—COMT—Metabolism—GSTP1—malignant glioma	0.000245	0.000479	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CB—malignant glioma	0.000244	0.000477	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAT—malignant glioma	0.000239	0.000467	CbGpPWpGaD
Methyldopa—SLC15A1—Transmembrane transport of small molecules—RAF1—malignant glioma	0.000228	0.000446	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PTK2—malignant glioma	0.000226	0.000442	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NCOR1—malignant glioma	0.000225	0.000441	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—IL2—malignant glioma	0.000224	0.000438	CbGpPWpGaD
Methyldopa—ADRA2A—G alpha (i) signalling events—CXCL8—malignant glioma	0.000223	0.000436	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—IDH2—malignant glioma	0.000213	0.000417	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDK—malignant glioma	0.00021	0.00041	CbGpPWpGaD
Methyldopa—DDC—Metabolism—CAV1—malignant glioma	0.000207	0.000405	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCR3—malignant glioma	0.000201	0.000394	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2B6—malignant glioma	0.0002	0.000392	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DTX1—malignant glioma	0.0002	0.000391	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—F2—malignant glioma	0.000192	0.000375	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—malignant glioma	0.00019	0.000372	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PDGFB—malignant glioma	0.00019	0.000371	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CG—malignant glioma	0.000188	0.000368	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—BDKRB2—malignant glioma	0.000184	0.00036	CbGpPWpGaD
Methyldopa—COMT—Metabolism—CAV1—malignant glioma	0.000184	0.000359	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—IDH1—malignant glioma	0.000183	0.000359	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCR3—malignant glioma	0.000183	0.000358	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PPARG—malignant glioma	0.000182	0.000356	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—CAV1—malignant glioma	0.00018	0.000352	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SPHK1—malignant glioma	0.000177	0.000347	CbGpPWpGaD
Methyldopa—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—malignant glioma	0.000177	0.000347	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP2C18—malignant glioma	0.000174	0.00034	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—F2—malignant glioma	0.000171	0.000335	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—FN1—malignant glioma	0.000171	0.000335	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—KNG1—malignant glioma	0.000168	0.000328	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CG—malignant glioma	0.000167	0.000327	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—BDKRB2—malignant glioma	0.000167	0.000327	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CD—malignant glioma	0.000166	0.000324	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CG—malignant glioma	0.000164	0.000321	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EGF—malignant glioma	0.000162	0.000317	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PPARG—malignant glioma	0.000161	0.000316	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PTPN11—malignant glioma	0.000161	0.000315	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SUFU—malignant glioma	0.000159	0.000311	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY2—malignant glioma	0.000157	0.000307	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GFAP—malignant glioma	0.000153	0.0003	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KNG1—malignant glioma	0.000152	0.000298	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT2—malignant glioma	0.00015	0.000293	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	0.000149	0.000291	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPHK1—malignant glioma	0.000148	0.00029	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CD—malignant glioma	0.000147	0.000288	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HEY1—malignant glioma	0.000145	0.000284	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR4—malignant glioma	0.000145	0.000284	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CB—malignant glioma	0.000144	0.000282	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CD—malignant glioma	0.000144	0.000282	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—malignant glioma	0.000143	0.00028	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIST1H3B—malignant glioma	0.000141	0.000276	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—malignant glioma	0.000141	0.000275	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—malignant glioma	0.000135	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—MMP3—malignant glioma	0.000135	0.000264	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS1—malignant glioma	0.000132	0.000258	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG2—malignant glioma	0.000129	0.000252	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RAF1—malignant glioma	0.000129	0.000252	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CB—malignant glioma	0.000128	0.000251	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—malignant glioma	0.000127	0.000248	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CB—malignant glioma	0.000126	0.000246	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—malignant glioma	0.000125	0.000244	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—BCHE—malignant glioma	0.000122	0.000239	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—malignant glioma	0.000121	0.000237	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC5A5—malignant glioma	0.000121	0.000237	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—IL2—malignant glioma	0.000115	0.000226	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—malignant glioma	0.000111	0.000217	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H3F3A—malignant glioma	0.000109	0.000213	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2—malignant glioma	0.000108	0.000212	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR3—malignant glioma	0.000108	0.000211	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTRK2—malignant glioma	0.000105	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—YWHAE—malignant glioma	0.000105	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—malignant glioma	0.000105	0.000205	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DUSP6—malignant glioma	0.000104	0.000204	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CG—malignant glioma	0.000104	0.000203	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—JAG1—malignant glioma	0.000103	0.000201	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH3—malignant glioma	0.000102	0.0002	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FBXW7—malignant glioma	0.000101	0.000197	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB2—malignant glioma	9.88e-05	0.000193	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2—malignant glioma	9.83e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—malignant glioma	9.81e-05	0.000192	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTP1—malignant glioma	9.74e-05	0.000191	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT2—malignant glioma	9.48e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—malignant glioma	9.48e-05	0.000185	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CG—malignant glioma	9.41e-05	0.000184	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PTPN11—malignant glioma	9.25e-05	0.000181	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—malignant glioma	9.19e-05	0.00018	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CD—malignant glioma	9.11e-05	0.000178	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KNG1—malignant glioma	8.99e-05	0.000176	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NCOR1—malignant glioma	8.95e-05	0.000175	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PIK3CA—malignant glioma	8.8e-05	0.000172	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT2—malignant glioma	8.61e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NTRK1—malignant glioma	8.57e-05	0.000168	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—KRAS—malignant glioma	8.34e-05	0.000163	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CD—malignant glioma	8.27e-05	0.000162	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP3—malignant glioma	7.96e-05	0.000156	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CB—malignant glioma	7.94e-05	0.000155	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN2B—malignant glioma	7.89e-05	0.000154	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3CA—malignant glioma	7.82e-05	0.000153	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTK2—malignant glioma	7.67e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3CA—malignant glioma	7.66e-05	0.00015	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—malignant glioma	7.63e-05	0.000149	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HES1—malignant glioma	7.53e-05	0.000147	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCOR1—malignant glioma	7.49e-05	0.000146	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—malignant glioma	7.41e-05	0.000145	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RAF1—malignant glioma	7.39e-05	0.000144	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—malignant glioma	7.3e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—IL2—malignant glioma	7.29e-05	0.000143	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CB—malignant glioma	7.21e-05	0.000141	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—malignant glioma	7.19e-05	0.000141	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRA—malignant glioma	7.17e-05	0.00014	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—malignant glioma	6.96e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—malignant glioma	6.93e-05	0.000136	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CG—malignant glioma	6.65e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL2—malignant glioma	6.62e-05	0.00013	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TERT—malignant glioma	6.6e-05	0.000129	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFB—malignant glioma	6.44e-05	0.000126	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—malignant glioma	6.42e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR1—malignant glioma	6.41e-05	0.000125	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—malignant glioma	6.38e-05	0.000125	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—malignant glioma	6.31e-05	0.000123	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—malignant glioma	6.26e-05	0.000122	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—malignant glioma	6.1e-05	0.000119	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—malignant glioma	6.04e-05	0.000118	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CD—malignant glioma	5.85e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—malignant glioma	5.81e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2—malignant glioma	5.81e-05	0.000114	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BAD—malignant glioma	5.74e-05	0.000112	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—malignant glioma	5.69e-05	0.000111	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CD80—malignant glioma	5.57e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APC—malignant glioma	5.56e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CG—malignant glioma	5.56e-05	0.000109	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGF—malignant glioma	5.5e-05	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN11—malignant glioma	5.46e-05	0.000107	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BRAF—malignant glioma	5.23e-05	0.000102	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CB—malignant glioma	5.1e-05	9.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT2—malignant glioma	5.09e-05	9.95e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—malignant glioma	5.07e-05	9.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—malignant glioma	5.05e-05	9.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CD—malignant glioma	4.89e-05	9.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3CA—malignant glioma	4.84e-05	9.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—KRAS—malignant glioma	4.79e-05	9.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—malignant glioma	4.68e-05	9.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—malignant glioma	4.4e-05	8.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3CA—malignant glioma	4.4e-05	8.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MDM2—malignant glioma	4.38e-05	8.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RAF1—malignant glioma	4.36e-05	8.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ERBB2—malignant glioma	4.32e-05	8.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CB—malignant glioma	4.26e-05	8.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—malignant glioma	4.09e-05	8.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—malignant glioma	3.95e-05	7.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASP3—malignant glioma	3.92e-05	7.66e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL2—malignant glioma	3.91e-05	7.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—malignant glioma	3.7e-05	7.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—malignant glioma	3.68e-05	7.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—malignant glioma	3.59e-05	7.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—malignant glioma	3.33e-05	6.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STAT3—malignant glioma	3.29e-05	6.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3CA—malignant glioma	3.11e-05	6.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—malignant glioma	3.06e-05	5.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—malignant glioma	2.99e-05	5.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KRAS—malignant glioma	2.83e-05	5.53e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3CA—malignant glioma	2.6e-05	5.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—malignant glioma	2.54e-05	4.96e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—malignant glioma	2.51e-05	4.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—malignant glioma	2.12e-05	4.15e-05	CbGpPWpGaD
